To identify drugs that might cooperate with NEDD8 inhibition, we performed an shRNA-based “drop-out” loss-of-function synthetic lethality screening on four CRC cell lines selected from a large collection [19] for known levels of sensitivity to pevonedistat and molecular features covering CRC heterogeneity [14]. The gene discussed is NEDD8; the disease is colorectal carcinoma.